Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Rapid and sensitive in vivo detection of opioid peptides

Award Number: R21DA048650
ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 03/01/2019
PERIOD OF PERFORMANCE END DATE: 02/28/2022

Group Awards By:

View Award Description

Rapid and sensitive in vivo detection of opioid peptides - Project Summary The goals of this research are two fold: to better understand the role of dynorphin during fentanyl withdrawal and to develop innovative, novel approaches to allow in vivo detection of endogenously release opioids. The ability to better understand how dynorphin drives negative affect associated with drug withdrawal will be critical in reducing the incidence of relapse and overdose and allow us to consider alternative more affective long-term treatments for addiction. The US Department of Health states that 42,249 people died from overdosing on opioids in 2016, 2.1 million people had an opioid use disorder and the economic cost of this epidemic was $504 billion, but is still rising along with the number of people afflicted. The reasons for this are multifaceted, but include a deep lack of understanding of how opioids alter brain circuitry to cause analgesia- which is good, but also what happens to brain circuitry to drive addiction- which is bad. We also know that pain and addiction are co-morbid with other mental health diseases such as anxiety, depression and stress, which makes cohesive research challenging. The first aim of this proposal will directly measure in vivo changes in dynorphin levels in the nucleus accumbens during withdrawal from Fentanyl. Fentanyl is 80 times more potent than morphine in vivo; its rapid onset of action not only increases the risk of addiction but likely increases the severity of withdrawal symptoms. We will use liquid chromatography/mass spectrometry which will allow detection in sub-fmol range. The second aim focuses on the development of micro-immunoelectrodes to allow more spatiotemporally controlled detection of opioid peptide release in vivo. This technology will allow us to detect peptides changes on a second to minute timescale. The combination of these techniques will, for the first time, allow us to detect dynamic changes in opioid peptides in vivo. Importantly, this will facilitate our knowledge and ability to better treat addiction, but is also very much applicable to multiple disease states and neuropeptides biology in general.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2023 ( Subtotal = $0 )
2023	2020	UNIVERSITY OF HEALTH SCIENCES AND PHARMACY IN ST. LOUIS	1 PHARMACY PL	SAINT LOUIS	MO	63110	SAINT LOUIS CITY	USA	Drug Use and Addiction Research Programs	000	2	4/13/2023	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2020 ( Subtotal = $197,805 )
2020	2020	ST. LOUIS COLLEGE OF PHARMACY	4588 PARKVIEW PL	SAINT LOUIS	MO	63110	SAINT LOUIS CITY	USA	Drug Use and Addiction Research Programs	001	2	2/28/2020	NON-COMPETING CONTINUATION	$197,805
2020	2019	ST. LOUIS COLLEGE OF PHARMACY	4588 PARKVIEW PL	SAINT LOUIS	MO	63110	SAINT LOUIS CITY	USA	Drug Use and Addiction Research Programs	000	1	12/16/2019	NEW	$0
														Subtotal = $197,805

Issue Date FY: 2019 ( Subtotal = $243,248 )
2019	2019	ST. LOUIS COLLEGE OF PHARMACY	4588 PARKVIEW PL	SAINT LOUIS	MO	63110	SAINT LOUIS CITY	USA	Drug Use and Addiction Research Programs	000	1	2/26/2019	NEW	$243,248
														Subtotal = $243,248

Grand Total All Awards = $441,053

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Rapid and sensitive in vivo detection of opioid peptides

Award Number: R21DA048650

ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 03/01/2019

PERIOD OF PERFORMANCE END DATE: 02/28/2022

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer